Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > FDA approval numbers.
View:
Post by beechguy on Jun 04, 2015 2:49pm

FDA approval numbers.

I know this has been a total shite show up to this point, however when FDA approves MCNA (IMVYON) our share price will be well over $3 a share not over $1 as you suggest. 3 weeks till successful submission, 4 weeks till US partnership. No financing. Book it Yankee. I know you own a lot of shares and are jaded by the frequent miss steps of our previous regime, but aside from a lousy financing the new crew haven't let us down yet. I suspect they won't either. In 1 month we will have 40mm in cash and primed for a real run up. Mark your calendar!! Beech
Comment by DamnYankees on Jun 04, 2015 3:39pm
BG, I have changed my opinion on that the $1.00 target a while back. I don't think MCNA will be a Telesta property when the FDA gives the go ahead. But I am not sure why it is that you think they need to raise 40 mil? I think that doubling the float is idiotic. 6 months cash is fine. Why give them enough to stall and delay for another 3 years.
Comment by ragingbull1327 on Jun 04, 2015 5:17pm
Most people should realize that $1 per share = roughly $170 million, which represents a value of neither here nor there.   So a guess of $1 is as arbitrary as a stock price of $100.    It's meaningless.   I think your $3 target is also low, unless they offer 100 million new shares to the market.  they discover this treatment, fight like H to get it approved, will do ...more  
Comment by ragingbull1327 on Jun 04, 2015 5:33pm
If they don't dilute this beast any further, I'll guess $5.20 a share.   885 mil.   Even 885 mil seems like chump change when you see 5.5 billion naive dollars still in Blackberry
Comment by ragingbull1327 on Jun 04, 2015 6:33pm
885 Canadian $.   Minimum.   Or they need a new agent.   I thought 1 billion was the new one million anyways.  Only in the USA, would a company pay 19 billion for WhatsApp, but try and scrounge together pesos to get behind an anti cancer treatment for as cheap as possible....
Comment by loveshackdave on Jun 04, 2015 5:47pm
You should be hoping for a financing beech, it will dilute shareholder value far less than a partnership will. They don't need $40mil to make it to approval and you better believe they will pay through the nose for it in a partnership.
Comment by DamnYankees on Jun 04, 2015 8:57pm
LSD, you strike me as someone who will spend his entire career arriving 5 minutes late for the subway. What aren't you getting about Telesta? Absolutely no one, outside of a few retail holders, takes the company or its BLA submission seriously. what a financing does is cement the the failure of TST in the minds of those on the sidelines, where a partner adds something they sorely lack ...more  
Comment by ragingbull1327 on Jun 05, 2015 9:24am
So you think they get thru 2008/2009 and then fail now?   That's an interesting perspective.   ;)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities